Hee Seung Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hee Seung Hong has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Byong Duk Ye
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
6 shared publications - Sang Hyoung Park
Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
6 shared publications - Suk-Kyun Yang
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5 shared publications - Sung Wook Hwang
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4 shared publications - Dong-Hoon Yang
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3 shared publications - Jeong-Sik Byeon
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 455-463
Prevalence and risk factors of gallstone disease in Korean patients with ulcerative colitis
Background/Aims: The prevalence of gallstone disease in patients with ulcerative colitis (UC) is higher than in the general population. However, risk factors of gallstone disease in these patients remain unclear. Thus, we investigated the prevalence and risk factors of gallstone disease in Korean patients with UC. Methods: Patients diagnosed with UC who underwent abdominal imaging studies between 1997 and 2020 were investigated using a well-established referral center-based large volume inflammatory bowel disease cohort. The prevalence and clinical characteristics of patients with gallstone disease were evaluated and compared with those without gallstone disease. Results: Overall, 2,811 patients with UC were enrolled. During the follow-up period (mean, 5.7 years), 198 patients (7.0%) were diagnosed with gallstone disease and compared with those without gallstone disease (n = 2,613). The proportion of extensive colitis at maximum extent, primary sclerosing cholangitis (PSC), history of cytomegalovirus, corticosteroid use, immunomodulatory use, colectomy, and appendectomy were significantly higher in the gallstone group (all P< 0.05). In multivariate analyses, age ≥ 60 years at gallstone evaluation (odds ratio [OR], 1.027; 95% confidence interval [CI], 1.002–1.052; P= 0.033), PSC (OR, 6.304; 95% CI, 3.162–12.565; P< 0.001), and history of colectomy (OR, 2.494; 95% CI, 1.222–5.087; P= 0.012) were significant risk factors for gallstone disease in patients with UC. Conclusions: The prevalence of gallstone disease in Korean patients with UC was 7.0%, and age ≥ 60 years at gallstone evaluation, PSC, and history of colectomy were significant risk factors for UC patients with gallstone disease.
- 31 October 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 455-463
Open AccessPrevalence and risk factors of gallstone disease in Korean patients with ulcerative colitis
Background/Aims: The prevalence of gallstone disease in patients with ulcerative colitis (UC) is higher than in the general population. However, risk factors of gallstone disease in these patients remain unclear. Thus, we investigated the prevalence and risk factors of gallstone disease in Korean patients with UC. Methods: Patients diagnosed with UC who underwent abdominal imaging studies between 1997 and 2020 were investigated using a well-established referral center-based large volume inflammatory bowel disease cohort. The prevalence and clinical characteristics of patients with gallstone disease were evaluated and compared with those without gallstone disease. Results: Overall, 2,811 patients with UC were enrolled. During the follow-up period (mean, 5.7 years), 198 patients (7.0%) were diagnosed with gallstone disease and compared with those without gallstone disease (n = 2,613). The proportion of extensive colitis at maximum extent, primary sclerosing cholangitis (PSC), history of cytomegalovirus, corticosteroid use, immunomodulatory use, colectomy, and appendectomy were significantly higher in the gallstone group (all P< 0.05). In multivariate analyses, age ≥ 60 years at gallstone evaluation (odds ratio [OR], 1.027; 95% confidence interval [CI], 1.002–1.052; P= 0.033), PSC (OR, 6.304; 95% CI, 3.162–12.565; P< 0.001), and history of colectomy (OR, 2.494; 95% CI, 1.222–5.087; P= 0.012) were significant risk factors for gallstone disease in patients with UC. Conclusions: The prevalence of gallstone disease in Korean patients with UC was 7.0%, and age ≥ 60 years at gallstone evaluation, PSC, and history of colectomy were significant risk factors for UC patients with gallstone disease.
- Open Access
- 31 January 2023
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 21 (1) , 137-147
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Background/Aims: We investigated the real-world effectiveness and safety of ustekinumab (UST) as induction treatment for Koreans with Crohn’s disease (CD).Methods: CD patients who started UST were prospectively enrolled from 4 hospitals in Korea. All enrolled patients received intravenous UST infusion at week 0 and subcutaneous UST injection at week 8. Clinical outcomes were assessed using Crohn’s Disease Activity Index (CDAI) scores at weeks 8 and 20 among patients with active disease (CDAI ≥150) at baseline. Clinical remission was defined as a CDAI <150, and clinical response was defined as a reduction in CDAI ≥70 points from baseline. Safety and factors associated with clinical remission at week 20 were also analyzed.Results: Sixty-five patients were enrolled between January 2019 and December 2020. Among 49 patients with active disease at baseline (CDAI ≥150), clinical remission and clinical response at week 8 were achieved in 26 (53.1%) and 30 (61.2%) patients, respectively. At week 20, 27 (55.1%) and 35 (71.4%) patients achieved clinical remission and clinical response, respectively. Twenty-seven patients (41.5%) experienced adverse events, with serious adverse events in 3 patients (4.6%). One patient (1.5%) stopped UST therapy due to poor response. Underweight (body mass index <18.5 kg/m2) (odds ratio [OR], 0.085; 95% confidence interval [CI], 0.014–0.498; P=0.006) and elevated C-reactive protein at baseline (OR, 0.133; 95% CI, 0.022–0.823; P=0.030) were inversely associated with clinical remission at week 20.Conclusions: UST was effective and well-tolerated as induction therapy for Korean patients with CD.
- 31 January 2023
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 21 (1) , 137-147
Open AccessReal-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Background/Aims: We investigated the real-world effectiveness and safety of ustekinumab (UST) as induction treatment for Koreans with Crohn’s disease (CD).Methods: CD patients who started UST were prospectively enrolled from 4 hospitals in Korea. All enrolled patients received intravenous UST infusion at week 0 and subcutaneous UST injection at week 8. Clinical outcomes were assessed using Crohn’s Disease Activity Index (CDAI) scores at weeks 8 and 20 among patients with active disease (CDAI ≥150) at baseline. Clinical remission was defined as a CDAI <150, and clinical response was defined as a reduction in CDAI ≥70 points from baseline. Safety and factors associated with clinical remission at week 20 were also analyzed.Results: Sixty-five patients were enrolled between January 2019 and December 2020. Among 49 patients with active disease at baseline (CDAI ≥150), clinical remission and clinical response at week 8 were achieved in 26 (53.1%) and 30 (61.2%) patients, respectively. At week 20, 27 (55.1%) and 35 (71.4%) patients achieved clinical remission and clinical response, respectively. Twenty-seven patients (41.5%) experienced adverse events, with serious adverse events in 3 patients (4.6%). One patient (1.5%) stopped UST therapy due to poor response. Underweight (body mass index <18.5 kg/m2) (odds ratio [OR], 0.085; 95% confidence interval [CI], 0.014–0.498; P=0.006) and elevated C-reactive protein at baseline (OR, 0.133; 95% CI, 0.022–0.823; P=0.030) were inversely associated with clinical remission at week 20.Conclusions: UST was effective and well-tolerated as induction therapy for Korean patients with CD.
- Open Access
- 25 May 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (6) , 942-951
Clinical and Genetic Characteristics of Korean Patients Diagnosed with Chronic Enteropathy Associated with SLCO2A1 Gene: A KASID Multicenter Study
Hee Seung Hong, Jiwon Baek, Jae Chul Park, Ho-Su Lee, Dohoon Park, A-Ran Yoon, Soo Jung Park, Sung Noh Hong, Seong-Joon Koh, Chang Kyun Lee, Bo-In Lee, Sung Wook Hwang, Sang Hyoung Park, Seung-Jae Myung, Suk-Kyun Yang, Kyuyoung Song, and Byong Duk Ye, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Gut and Liver 2022;16:942-51. https://doi.org/10.5009/gnl210415
- 25 May 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (6) , 942-951
Open AccessClinical and Genetic Characteristics of Korean Patients Diagnosed with Chronic Enteropathy Associated with SLCO2A1 Gene: A KASID Multicenter Study
Hee Seung Hong, Jiwon Baek, Jae Chul Park, Ho-Su Lee, Dohoon Park, A-Ran Yoon, Soo Jung Park, Sung Noh Hong, Seong-Joon Koh, Chang Kyun Lee, Bo-In Lee, Sung Wook Hwang, Sang Hyoung Park, Seung-Jae Myung, Suk-Kyun Yang, Kyuyoung Song, and Byong Duk Ye, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Gut and Liver 2022;16:942-51. https://doi.org/10.5009/gnl210415
- Open Access
- 30 April 2022
- Published by The Ewha Medical Journal, Ewha Womans University College of Medicine in Ewha Medical Journal
- Vol. 45 (2) , 35-45
Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors
Inflammatory bowel disease (IBD) is a chronic inflammatory disease that occurs in the gastrointestinal tract that includes Crohn’s disease (CD) and ulcerative colitis (UC), and that may sometimes present with extraintestinal manifestations [1,2]. The prevalence of IBD is increasing in Asian countries including Korea [3-5]. Symptoms such as abdominal pain, diarrhea, weight loss, and a bloody stool are common to IBD. If the inflammation is not well controlled in affected patients, complications including intestinal stricture, fistula, perforation, and cancer can occur [6-8]. IBD is also a progressive disease, and it is important therefore to maintain appropriate medical interventions to prevent disease progression and reduce complications [9,10]. Adherence to medication regimens is thus vital and several studies have indicated in this regard that the prognosis is poorer in non-adherent IBD patients [11].
- 30 April 2022
- Published by The Ewha Medical Journal, Ewha Womans University College of Medicine in Ewha Medical Journal
- Vol. 45 (2) , 35-45
Open AccessMedication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors
Inflammatory bowel disease (IBD) is a chronic inflammatory disease that occurs in the gastrointestinal tract that includes Crohn’s disease (CD) and ulcerative colitis (UC), and that may sometimes present with extraintestinal manifestations [1,2]. The prevalence of IBD is increasing in Asian countries including Korea [3-5]. Symptoms such as abdominal pain, diarrhea, weight loss, and a bloody stool are common to IBD. If the inflammation is not well controlled in affected patients, complications including intestinal stricture, fistula, perforation, and cancer can occur [6-8]. IBD is also a progressive disease, and it is important therefore to maintain appropriate medical interventions to prevent disease progression and reduce complications [9,10]. Adherence to medication regimens is thus vital and several studies have indicated in this regard that the prognosis is poorer in non-adherent IBD patients [11].
- Open Access
- 1 January 2022
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 37 (1) , 73-84
Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases
Background/Aims: Data on the immunoprotective status against measles, mumps, rubella, varicella zoster virus (VZV), hepatitis A virus (HAV), and Epstein-Barr virus (EBV) infection in patients with inflammatory bowel disease (IBD) are still lacking. Therefore, we investigated the seropositivity rates for viral infectious diseases and the associated factors in Korean patients with IBD.Methods: In this retrospective cohort study, serum immunoglobulin G antibody positivity rates against measles virus, mumps virus, rubella virus, VZV, HAV, and EBV viral capsid antigen (VCA) were measured in patients with Crohn’s disease or ulcerative colitis (UC) who first visited the IBD clinic. Seropositivity rates and their associated factors were analyzed.Results: Between January 2016 and December 2018, 263 patients were enrolled (male, 167 [67.3%]; UC, 134 [50.9%]). The median age at serological test was 30 years (interquartile range, 22 to 46). The seropositivity rates were 84.0%, 85.2%, 66.5%, 87.4%, 50.0%, and 93.7% for measles, mumps, rubella, VZV, HAV, and EBV, respectively. Younger age at serological test was associated with seronegative status for measles (adjusted odds ratio [aOR], 0.92; 95% confidence interval [CI], 0.88 to 0.96), VZV (aOR, 0.83; 95% CI, 0.74 to 0.93), and HAV (aOR, 0.93; 95% CI, 0.91 to 0.95). Furthermore, IBD type-UC was associated with seronegative status against VZV (aOR, 0.33; 95% CI, 0.11 to 0.99).Conclusions: Seropositivity rates for common viral infectious diseases in Korean patients with IBD were similar to those of the general population. In the younger age group, protective immunity against measles, VZV, and HAV is required, with proper vaccination, as necessary.
- 1 January 2022
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 37 (1) , 73-84
Open AccessSeroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases
Background/Aims: Data on the immunoprotective status against measles, mumps, rubella, varicella zoster virus (VZV), hepatitis A virus (HAV), and Epstein-Barr virus (EBV) infection in patients with inflammatory bowel disease (IBD) are still lacking. Therefore, we investigated the seropositivity rates for viral infectious diseases and the associated factors in Korean patients with IBD.Methods: In this retrospective cohort study, serum immunoglobulin G antibody positivity rates against measles virus, mumps virus, rubella virus, VZV, HAV, and EBV viral capsid antigen (VCA) were measured in patients with Crohn’s disease or ulcerative colitis (UC) who first visited the IBD clinic. Seropositivity rates and their associated factors were analyzed.Results: Between January 2016 and December 2018, 263 patients were enrolled (male, 167 [67.3%]; UC, 134 [50.9%]). The median age at serological test was 30 years (interquartile range, 22 to 46). The seropositivity rates were 84.0%, 85.2%, 66.5%, 87.4%, 50.0%, and 93.7% for measles, mumps, rubella, VZV, HAV, and EBV, respectively. Younger age at serological test was associated with seronegative status for measles (adjusted odds ratio [aOR], 0.92; 95% confidence interval [CI], 0.88 to 0.96), VZV (aOR, 0.83; 95% CI, 0.74 to 0.93), and HAV (aOR, 0.93; 95% CI, 0.91 to 0.95). Furthermore, IBD type-UC was associated with seronegative status against VZV (aOR, 0.33; 95% CI, 0.11 to 0.99).Conclusions: Seropositivity rates for common viral infectious diseases in Korean patients with IBD were similar to those of the general population. In the younger age group, protective immunity against measles, VZV, and HAV is required, with proper vaccination, as necessary.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 14
Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Immunomodulators remain fundamental for the medical treatment of Crohn’s disease (CD). Methotrexate (MTX) is widely used as a second-line immunomodulator; however, there is a lack of recent data on MTX monotherapy among the Asian population with CD. Therefore, in this study, we aimed to investigate the tolerability and clinical outcomes of MTX in Korean patients with CD. A retrospective chart review was performed for CD patients treated with MTX monotherapy or in combination with 5-aminosalicylic acid (5-ASA), at the Asan Medical Center, Seoul, South Korea. The tolerability of MTX monotherapy within 6 months was assessed and the clinical effectiveness of MTX was evaluated based on the Crohn’s disease activity index (CDAI). In total, 85 patients were included, of which 29 (34.1%) discontinued MTX due to intolerability during the follow-up. Adverse events (AEs) were reported in 41 (48.2%) patients. The most common AE was gastrointestinal disorders (17/41) and only one patient experienced a serious AE, a systemic infection that required hospitalization. Among the 56 patients who tolerated MTX within 6 months, 44 (65.9%) showed a clinical response. Moreover, no factor was significantly associated with intolerability. The administration method was the only factor significantly associated with a response to MTX (p = 0.041). The adjusted odds ratio of parenteral injection compared to oral administration was 5.68 (95% confidence interval (CI), 1.07–30.08). In this study, one-third of patients were intolerant to MTX; nonetheless, the response rate was as high as 65.9% among tolerant patients. In addition, no significant factors affected intolerability. In terms of the clinical response, parenteral injection could be better than oral administration.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 14
Open AccessShort-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Immunomodulators remain fundamental for the medical treatment of Crohn’s disease (CD). Methotrexate (MTX) is widely used as a second-line immunomodulator; however, there is a lack of recent data on MTX monotherapy among the Asian population with CD. Therefore, in this study, we aimed to investigate the tolerability and clinical outcomes of MTX in Korean patients with CD. A retrospective chart review was performed for CD patients treated with MTX monotherapy or in combination with 5-aminosalicylic acid (5-ASA), at the Asan Medical Center, Seoul, South Korea. The tolerability of MTX monotherapy within 6 months was assessed and the clinical effectiveness of MTX was evaluated based on the Crohn’s disease activity index (CDAI). In total, 85 patients were included, of which 29 (34.1%) discontinued MTX due to intolerability during the follow-up. Adverse events (AEs) were reported in 41 (48.2%) patients. The most common AE was gastrointestinal disorders (17/41) and only one patient experienced a serious AE, a systemic infection that required hospitalization. Among the 56 patients who tolerated MTX within 6 months, 44 (65.9%) showed a clinical response. Moreover, no factor was significantly associated with intolerability. The administration method was the only factor significantly associated with a response to MTX (p = 0.041). The adjusted odds ratio of parenteral injection compared to oral administration was 5.68 (95% confidence interval (CI), 1.07–30.08). In this study, one-third of patients were intolerant to MTX; nonetheless, the response rate was as high as 65.9% among tolerant patients. In addition, no significant factors affected intolerability. In terms of the clinical response, parenteral injection could be better than oral administration.